Fulcrum Therapeutics, Inc. (FULC)
| Market Cap | 383.10M |
| Revenue (ttm) | 4.60M |
| Net Income (ttm) | -69.22M |
| Shares Out | 27.26M |
| EPS (ttm) | -14.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $13.87 |
| Previous Close | $13.95 |
| Change ($) | -0.08 |
| Change (%) | -0.57% |
| Day's Open | 14.00 |
| Day's Range | 13.44 - 14.13 |
| Day's Volume | 88,562 |
| 52-Week Range | 7.22 - 22.06 |
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with geneti...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with geneti...
Owen Wallace to Transition to Scientific Advisory Board Owen Wallace to Transition to Scientific Advisory Board
Event will review the company's novel approach to inducing fetal hemoglobin
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genet...
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genet...
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics (FULC).
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058 Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genet...
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with gen...
- Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) revealed late last week his firm upped its stake in Dave & Buster's Entertainment Inc.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with g...
Fulcrum Therapeutics Inc. (FULC) CEO Robert Gould on Q2 2020 Results - Earnings Call Transcript
– Conference call scheduled for 8:00 a.m. ET today –
Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expression
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.
Fulcrum Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression Collaboration w...
Fulcrum stock gapped up Wednesday after the Food and Drug Administration gave it the go-ahead to begin a coronavirus treatment study. The drug is also in testing for muscular dystrophy.
The U.S. Food and Drug Administration (FDA) has notified Fulcrum Therapeutics Inc.
Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Fulcrum receives early notification from U.S. Food and Drug Administration (FDA) that study may proceed Fulcrum receives early notification from U.S. Food and Drug Administration (FDA) that st...
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced the closing of a $68.5 million private placement pursuant to a securities pu...
Investigational New Drug (IND) application submitted; Company preparing to initiate Phase 3 trial
As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q1 2020 Results - Earnings Call Transcript
Conference call scheduled for 8:00 a.m. ET today Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with g...
CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with g...
– Losmapimod achieves target engagement in muscle –
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q4 2019 Results - Earnings Call Transcript
CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ge...
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ge...
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.
Fulcrum Therapeutics' (FULC) CEO Robert Gould on Q3 2019 Results - Earnings Call Transcript
Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumer...
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Strode brings experience leading regulatory affairs and quality assurance across multiple therapeutic areas, including rare diseases with high unmet need
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
– Completed initial public offering, raising $72.0 million in gross proceeds –
CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ge...
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) made its public debut on Thursday morning, opening at $14.50 after being priced at $16 per share.
About FULC
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upre... [Read more...]
| Industry Biotechnology | IPO Date Jul 18, 2019 |
| CEO Dr. Robert J. Gould | Employees 73 |
| Stock Exchange NASDAQ | Ticker Symbol FULC |
Analyst Forecasts
According to 5 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is 18.17, which is an increase of 31.00% from the latest price.